{"organizations": [], "uuid": "82e12d257d80ffabad29ee7d5bc67706abc57153", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bellerophon-reaches-agreement-with/brief-bellerophon-reaches-agreement-with-fda-on-study-design-of-phase-2b-trial-of-inopulse-idUSASC0A0HE", "country": "US", "domain_rank": 408, "title": "BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.958, "site_type": "news", "published": "2018-05-08T20:40:00.000+03:00", "replies_count": 0, "uuid": "82e12d257d80ffabad29ee7d5bc67706abc57153"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bellerophon-reaches-agreement-with/brief-bellerophon-reaches-agreement-with-fda-on-study-design-of-phase-2b-trial-of-inopulse-idUSASC0A0HE", "ord_in_thread": 0, "title": "BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "bellerophon therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Bellerophon Therapeutics Inc:\n* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE\n* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE\n* BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS\n* BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T20:40:00.000+03:00", "crawled": "2018-05-09T12:15:58.026+03:00", "highlightTitle": ""}